Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Calliditas Therapeutics in connection with a directed share issue
Mandate

Vinge advises Calliditas Therapeutics in connection with a directed share issue

August 17, 2021 Capital Markets and Public M&A

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with a directed share issue whereby the company will raise proceeds of approximately SEK 324 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Benjamin Vafaeian.

Related

Vinge has advised private equity firm Stirling Square Capital Partners

 Vinge has advised private equity firm Stirling Square Capital Partners in connection with its acquisition of a majority stake in Infobric, a leading provider of software solutions for the construction industry, from Summa Equity.
September 22, 2023

Vinge advises Stendörren in connection with issuance of green notes and tender offer

 Vinge has advised Stendörren Fastigheter AB in connection with its issuance of senior unsecured green notes in an amount of SEK 500 million (within a framework of SEK 600 million) and its parallel tender offer in respect of its previously issued notes due 2024.
September 21, 2023

Vinge has advised Elektroskandia in connection with its majority investment in Aprilice

 Vinge has advised Elektroskandia (a Sonepar company) in connection with its acquisition of 70% of the shares in Aprilice, one of the leading solar energy platforms in Northern Europe.
September 20, 2023